293 filings
8-K
RVPH
Reviva Pharmaceuticals Holdings Inc.
15 Apr 24
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
5:01pm
10-K
2023 FY
RVPH
Reviva Pharmaceuticals Holdings Inc.
Annual report
15 Apr 24
8:22am
8-K
RVPH
Reviva Pharmaceuticals Holdings Inc.
15 Apr 24
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
8:20am
8-K
RVPH
Reviva Pharmaceuticals Holdings Inc.
15 Apr 24
Results of Operations and Financial Condition
7:45am
NT 10-K
RVPH
Reviva Pharmaceuticals Holdings Inc.
2 Apr 24
Notice of late annual filing
8:00am
SC 13D/A
qoj77ivpu
16 Feb 24
REVIVA PHARMACEUTICALS / Bhat Laxminarayan ownership change
4:32pm
SC 13G/A
sl10o1h
14 Feb 24
REVIVA PHARMACEUTICALS / TANG CAPITAL PARTNERS ownership change
4:00pm
SC 13G
dbmrws 1v09n6hqlk
14 Feb 24
REVIVA PHARMACEUTICALS / ARMISTICE CAPITAL ownership change
3:52pm
EFFECT
niojlyw98s
14 Feb 24
Notice of effectiveness
12:15am
424B4
mb1sli0y
13 Feb 24
Prospectus supplement with pricing info
5:00pm
CORRESP
tww516a5s nsnnijr2lu
9 Feb 24
Correspondence with SEC
12:00am
UPLOAD
wtl4qmykzw22i xjw
9 Feb 24
Letter from SEC
12:00am
SC 13D/A
8013lcnldbfa7
30 Nov 23
REVIVA PHARMACEUTICALS / VEDANTA PARTNERS ownership change
4:49pm
4
94vc4469f6j
22 Nov 23
REVIVA PHARMACEUTICALS / PARAG SAXENA ownership change
6:28pm
8-K
g56ep7zdq 7e
17 Nov 23
Reviva Announces $30 Million Registered Direct Offering PricedĀ At-the-MarketĀ Under Nasdaq Rules
4:05pm
424B5
zwmxgm
17 Nov 23
Prospectus supplement for primary offering
4:03pm
8-K/A
47prlzkg8cyvh6gbqr
14 Nov 23
Changes in Registrant's Certifying Accountant
4:15pm
8-K
my3odoah lzt7gc
14 Nov 23
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
4:12pm
4
y8ayidoubglgxteq
14 Nov 23
REVIVA PHARMACEUTICALS / Richard A Margolin ownership change
12:00am